Related references
Note: Only part of the references are listed.Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation
Jin Seok Kim et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Impact of additional cytoreduction following autologous SCT in multiple myeloma
S. K. Kumar et al.
BONE MARROW TRANSPLANTATION (2008)
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
Bart Barlogie et al.
CANCER (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Relationship between depth of response and outcome in multiple myeloma
David Dingli et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
Bart Barlogie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe
J Fermand et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma
R Alexanian et al.
BONE MARROW TRANSPLANTATION (2004)
Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials
BGM Durie et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Single versus double autologous stem-cell transplantation for multiple myeloma
M Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
D Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
S Singhal et al.
BONE MARROW TRANSPLANTATION (2002)
Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
R Alexanian et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
